Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...
Candel Therapeutics, Inc. (NASDAQ:CADL) insiders who acquired shares over the previous 12 months, can probably afford to ignore the recent 19% decline in the stock price. After accounting for the ...
Fintel reports that on February 7, 2025, B of A Securities initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy recommendation. As of January 29, 2025, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback